A case analysis of acute-on-chronic liver failure caused by abiraterone

XIAO Zhun; DAI Jinghui; YAO Weili; MA Suping

doi:10.6039/j.issn.1001-0408.2023.14.13

您当前的位置：

首页 >

文章列表页 >

A case analysis of acute-on-chronic liver failure caused by abiraterone

更新时间：2025-09-27

- A case analysis of acute-on-chronic liver failure caused by abiraterone
- ZHONGGUO YAOFANG Vol. 34, Issue 14, Pages: 1730-1733(2023)
- 作者机构：
  
  河南中医药大学第一附属医院脾胃肝胆病科，郑州　450003
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.14.13
  CLC： R969.3;R979.1
- Received：10 December 2022，
  
  Revised：2023-06-28，
  
  Accepted：28 June 2023，
  
  Published：30 July 2023
- 稿件说明：
移动端阅览
肖准,代静慧,姚伟丽,等.阿比特龙致慢加急性肝衰竭1例病例分析[J].中国药房,2023,34(14):1730-1733.

XIAO Zhun,DAI Jinghui,YAO Weili,et al.A case analysis of acute-on-chronic liver failure caused by abiraterone[J].ZHONGGUO YAOFANG,2023,34(14):1730-1733.
肖准,代静慧,姚伟丽,等.阿比特龙致慢加急性肝衰竭1例病例分析[J].中国药房,2023,34(14):1730-1733. DOI： 10.6039/j.issn.1001-0408.2023.14.13.

XIAO Zhun,DAI Jinghui,YAO Weili,et al.A case analysis of acute-on-chronic liver failure caused by abiraterone[J].ZHONGGUO YAOFANG,2023,34(14):1730-1733. DOI： 10.6039/j.issn.1001-0408.2023.14.13.

摘要

阿比特龙是治疗前列腺癌的常用靶向药物，其常见药品不良反应（ADR）包括肝功能异常、疲乏、恶心、水肿等。本文报道了1例入住河南中医药大学第一附属医院的78岁既往有乙型肝炎、肝硬化病史的前列腺恶性肿瘤切除术后患者，于入院1个月前开始应用阿比特龙，用药3周后出现消化道症状，4周时症状加重并伴皮肤、眼珠、小便发黄，5周（入院1周）后不幸死亡。结合检验检查结果，该患者被诊断为慢加急性肝衰竭（ACLF）。本文详细分析了该患者的病例情况及相关诊疗经过，并结合诺氏ADR评估量表评估出ACLF与阿比特龙的使用“很可能”相关，提示阿比特龙可能诱导肝硬化等慢性肝病患者出现肝衰竭的严重ADR；临床应动态检测该类患者的肝功能变化，必要时予以保肝药物预防性治疗。

Abstract

Abiraterone is commonly used as a targeted drug for the treatment of prostate cancer， which commonly causes adverse drug reactions （ADR）， including abnormal liver function， fatigue， nausea and edema， etc. This study reports a 78-year-old man with a history of hepatitis B and liver cirrhosis after prostate cancer resection who was admitted to the First Affiliated Hospital of Henan University of Chinese Medicine. The patient received abiraterone treatment 1 month before admission and developed gastrointestinal symptoms 3 weeks after the treatment and worsened at 4th week with yellowing of the skin， sclera and urine. Unfortunately， the patient died after 5 weeks of abiraterone treatment （1 week after admission）. Based on test and examination results， the patient was diagnosed with acute-on-chronic liver failure （ACLF）. This paper analyzes the patient’s medical history and the relevant treatment in detail. It is evaluated that ACLF and abiraterone are “probably” related based on Naranjo ADR Probability Scale， suggesting abiraterone may induce severe ADR of liver failure in patients with chronic liver diseases such as cirrhosis. These patients should be monitored dynamically for changes in liver function and treated prophylactically with liver-protective drugs if necessary.

关键词

Keywords

references

BAJAJ J S ， O’LEARY J G ， LAI J C ， et al . Acute-on-chronic liver failure clinical guidelines [J ] . Am J Gastroenterol ， 2022 ， 117 （ 2 ）： 225 - 252 .

FIZAZI K ， FOULON S ， CARLES J ， et al . Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer（PEACE-1）：a multicentre，open-label，randomised，phase 3 study with a 2×2 factorial design [J ] . Lancet ， 2022 ， 399 （ 10336 ）： 1695 - 1707 .

种玉良，孟勇，夏晓妹 . 阿比特龙治疗去势抵抗性前列腺癌疗效和安全性的Meta分析 [J ] . 中国循证医学杂志， 2022 ， 22 （ 3 ）： 276 - 283 .

COLOMBA E ， MARRET G ， BACIARELLO G ， et al . Liver tests increase on abiraterone acetate in men with metastatic prostate cancer：natural history，management and outcome [J ] . Eur J Cancer ， 2020 ， 129 ： 117 - 122 .

中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组 . 肝衰竭诊治指南：2018年版 [J ] . 临床肝胆病杂志， 2019 ， 35 （ 1 ）： 38 - 44 .

中国中西医结合学会 . 慢加急性肝衰竭中西医结合诊疗专家共识 [J ] . 临床肝胆病杂志， 2021 ， 37 （ 9 ）： 2045 - 2053 .

杨涛，那扎罗，吴登龙，等 . 阿比特龙药物代谢在前列腺癌治疗中的意义及研究进展 [J ] . 中国男科学杂志， 2021 ， 35 （ 1 ）： 60 - 63 .

BOUHAJIB M ， TAYAB Z . Evaluation of the pharmacokinetics of abiraterone acetate and abiraterone following single-dose administration of abiraterone acetate to healthy subjects [J ] . Clin Drug Investig ， 2019 ， 39 （ 3 ）： 309 - 317 .

KOROKI Y ， IMANAKA K ， YASUDA Y ， et al . Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer：a prospective，observational，post-marketing surveillance study [J ] . Jpn J Clin Oncol ， 2021 ， 51 （ 9 ）： 1452 - 1461 .

杜鸿，李俊，邱明星 . 阿比特龙治疗去势抵抗性前列腺癌安全性分析 [J ] . 实用医院临床杂志， 2019 ， 16 （ 3 ）： 33 - 35 .

YUMIBA S ， KOMORI K ， IWANISHI T ， et al . A case of fulminant hepatitis after administration of abiraterone ace-tate [J ] . Hinyokika Kiyo ， 2017 ， 63 （ 11 ）： 479 - 482 .

SINGH P ， SINHA A ， LAMA TAMANG T G ， et al . Abiraterone-associated fulminant liver failure [J ] . Am J Ther ， 2018 ， 25 （ 4 ）： e505 - e506 .

NARANJO C A ， BUSTO U ， SELLERS E M ， et al . A method for estimating the probability of adverse drug reactions [J ] . Clin Pharmacol Ther ， 1981 ， 30 （ 2 ）： 239 - 245 .

Views

219

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰